Michael Dal Bello is a Partner at Curewell Capital and has been involved in principal investing for over 25 years, primarily focused on the healthcare sector. Prior to co-founding Curewell Capital, Michael was Investment Partner and Head of Healthcare at Pritzker Private Capital, serving on the boards of Clinical Innovations, PathGroup, and KabaFusion. Prior to PPC, Michael was a Managing Director at Blackstone where he focused on healthcare and insurance and served on the boards of Alliant Insurance Services, Apria Healthcare, Biomet, Catalent, Emdeon (now Change Healthcare), TeamHealth and Vanguard Health Systems.

‍

During his tenure he worked with management teams to drive value through operational improvements, growth initiatives and acquisitions. He currently serves on the Board of Directors of Alliance for Multispecialty Research and WeInfuse.

‍

Before joining Blackstone, Michael worked at Hellman & Friedman and Bain & Company. Michael earned an MBA from Harvard Business School and a master’s degree in Philosophy, Politics and Economics from Balliol College at Oxford University where he was a Thouron Scholar. He received his undergraduate degrees from the Wharton School and the College of Arts & Sciences at the University of Pennsylvania. He is a Board Member of the UCLA Technology Development Group and the Luskin Orthopaedic Institute for Children at UCLA and is a former Chairman of the Healthcare Private Equity Association. He is a member of the Council on Foreign Relations.